Insider Selling: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells $147,533.25 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Pravin Dugel sold 21,475 shares of the firm’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the transaction, the insider now owns 3,520,318 shares of the company’s stock, valued at $24,184,584.66. The trade was a 0.61 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Ocular Therapeutix Trading Up 2.9 %

Shares of NASDAQ:OCUL opened at $7.14 on Friday. The company has a 50-day simple moving average of $7.92 and a 200 day simple moving average of $8.91. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The company has a market capitalization of $1.12 billion, a P/E ratio of -5.41 and a beta of 1.22. Ocular Therapeutix, Inc. has a 52-week low of $4.06 and a 52-week high of $11.77.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Ocular Therapeutix currently has an average rating of “Moderate Buy” and an average target price of $17.00.

Institutional Investors Weigh In On Ocular Therapeutix

Several hedge funds have recently bought and sold shares of OCUL. GF Fund Management CO. LTD. acquired a new stake in Ocular Therapeutix during the fourth quarter worth approximately $28,000. Atlas Capital Advisors Inc. acquired a new stake in Ocular Therapeutix during the fourth quarter worth approximately $43,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Ocular Therapeutix by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 1,015 shares during the last quarter. AlphaQuest LLC acquired a new stake in Ocular Therapeutix during the fourth quarter worth approximately $53,000. Finally, Capital Performance Advisors LLP acquired a new stake in Ocular Therapeutix during the third quarter worth approximately $70,000. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.